We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 108.24 | 109.30 | 109.37 | 0 | 00:00:00 |
From Dec 2019 to Dec 2024
By Colin Kellaher
Celgene Corp. (CELG) on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Revlimid in combination with rituximab for adults with previously treated follicular lymphoma.
The Summit, N.J., biopharmaceutical company said the combination, if approved by the European Commission, would be the first combination treatment regimen for patients with the blood cancer that doesn't include chemotherapy.
The European Commission, which generally follows the CHMP's recommendations, is expected to make its final decision in about two months, Celgene said.
Celgene in January agreed to be acquired by Bristol-Myers Squibb Co. (BMY) in a $74 billion deal expected to close by the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
November 15, 2019 08:07 ET (13:07 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
